PZENA INVESTMENT MANAGEMENT LLC: CVS HEALTH CORP (CVS): Quarterly 13F Position History
As of Q1 2026, PZENA INVESTMENT MANAGEMENT LLC reported 13,773,053 shares of CVS HEALTH CORP (CVS), worth $989.2M and representing 3.2% of its 13F equity book. Quarter-over-quarter share count change: 1,808,254 (-11.6%) . The position first appeared in Q2 2016 and has been disclosed across 40 13F-HR filings in Pactolio's tracked window.
- 13,773,053Shares Held (Latest Filing)
- $989.2MReported Market Value (Latest Filing)
- 3.2%Portfolio Weight (% of 13F Equity Book)
- 1,808,254Quarter-over-Quarter Share Change
- -$247.4MQuarter-over-Quarter Value Change
- 19,610,579Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 40 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 13,773,053 | 1,808,254 | -11.6% | $989.2M | 3.2% | $71.8 |
| Q4 2025 | 15,581,307 | 263,665 | -1.7% | $1.2B | 3.7% | $79.4 |
| Q3 2025 | 15,844,972 | 901,881 | -5.4% | $1.2B | 3.9% | $75.4 |
| Q2 2025 | 16,746,853 | 935,521 | -5.3% | $1.2B | 3.8% | $69.0 |
| Q1 2025 | 17,682,374 | 1,928,205 | -9.8% | $1.2B | 4.2% | $67.8 |
| Q4 2024 | 19,610,579 | +6,475,271 | +49.3% | $880.3M | 3.0% | $44.9 |
| Q3 2024 | 13,135,308 | +198,920 | +1.5% | $825.9M | 2.7% | $62.9 |
| Q2 2024 | 12,936,388 | +7,382,931 | +132.9% | $764.0M | 2.7% | $59.1 |
| Q1 2024 | 5,553,457 | +4,729,207 | +573.8% | $442.9M | 1.5% | $79.8 |
| Q4 2023 | 824,250 | +824,250 | — | $65.1M | 0.2% | $79.0 |
| Q3 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2023 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q2 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q1 2022 | 0 | 0 | — | $0 | 0.0% | — |
| Q4 2021 | 0 | 0 | — | $0 | 0.0% | — |
| Q3 2021 | 0 | 1,235,580 | -100.0% | $0 | 0.0% | — |
| Q2 2021 | 1,235,580 | +527 | +0.0% | $103.1M | 0.4% | $83.4 |
| Q1 2021 | 1,235,053 | +1,078 | +0.1% | $92.9M | 0.4% | $75.2 |
| Q4 2020 | 1,233,975 | +75,581 | +6.5% | $84.3M | 0.4% | $68.3 |
| Q3 2020 | 1,158,394 | +43,418 | +3.9% | $67.7M | 0.4% | $58.4 |
| Q2 2020 | 1,114,976 | 0 | — | $72.4M | 0.5% | $65.0 |
| Q1 2020 | 1,114,976 | +163,186 | +17.1% | $66.2M | 0.5% | $59.3 |
| Q4 2019 | 951,790 | 132 | -0.0% | $70.7M | 0.3% | $74.3 |
| Q3 2019 | 951,922 | +236,189 | +33.0% | $60.0M | 0.3% | $63.1 |
| Q2 2019 | 715,733 | 3,151 | -0.4% | $39.0M | 0.2% | $54.5 |
| Q1 2019 | 718,884 | +502 | +0.1% | $38.8M | 0.2% | $53.9 |
| Q4 2018 | 718,382 | 698 | -0.1% | $47.1M | 0.3% | $65.5 |
| Q3 2018 | 719,080 | 3,706 | -0.5% | $56.6M | 0.3% | $78.7 |
| Q2 2018 | 722,786 | +19,145 | +2.7% | $46.5M | 0.2% | $64.3 |
| Q1 2018 | 703,641 | +2,559 | +0.4% | $43.8M | 0.2% | $62.2 |
| Q4 2017 | 701,082 | +1,210 | +0.2% | $50.8M | 0.2% | $72.5 |
| Q3 2017 | 699,872 | 202 | -0.0% | $56.9M | 0.3% | $81.3 |
| Q2 2017 | 700,074 | +166,039 | +31.1% | $56.3M | 0.3% | $80.5 |
| Q1 2017 | 534,035 | +287 | +0.1% | $41.9M | 0.2% | $78.5 |
| Q4 2016 | 533,748 | +3,890 | +0.7% | $42.1M | 0.2% | $78.9 |
| Q3 2016 | 529,858 | 26 | -0.0% | $47.2M | 0.3% | $89.0 |
| Q2 2016 | 529,884 | — | — | $50.7M | 0.3% | $95.7 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did PZENA INVESTMENT MANAGEMENT LLC first disclose a CVS position in 13F-HR filings?
PZENA INVESTMENT MANAGEMENT LLC first reported CVS HEALTH CORP (CVS) on its 13F-HR filing for the period ending 2016-06-30 (Q2 2016). The position has appeared on 40 reported quarters within Pactolio's tracked window.
What was PZENA INVESTMENT MANAGEMENT LLC's most recent quarter-over-quarter share-count change in CVS?
Between Q4 2025 and Q1 2026, PZENA INVESTMENT MANAGEMENT LLC reduced its CVS position by 1,808,254 shares (-11.6%), leaving 13,773,053 shares at a market value of $989.2M.
Does the implied price-per-share represent PZENA INVESTMENT MANAGEMENT LLC's cost basis in CVS?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.